Clone:
T6D11
Type of antibody:
Primary antibodies
Isotype:
mouse IgG2b

Specifications for CD45RA antibodies

Overview

T6D11 recognizes the human CD45RA antigen which is expressed on naive CD4
+
and CD8
+
T cells as well as on CD8
+
effector T cells. CD45RA is also present on subsets of B and NK cells as well as on plasmacytoid dendritic cells. The CD45RA antibody recognizes the 220 kDa isoform of the leukocyte common antigen (LCA), a transmembrane tyrosine phosphatase.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD45RA may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Detailed product information

Technical specifications

CloneT6D11
Isotypemouse IgG2b
Type of antibodyPrimary antibodies
Specieshuman
AntigenCD45RA
Molecular mass of antigen [kDa]145
Distribution of antigenB cells, monocytes, NK cells, T cells, thymocytes

Resources for CD45RA antibodies

Certificates

Please follow this
link
to download the Certificate of Conformity (CoC) by lot number.

References for CD45RA antibodies

Publications

  1. Braun, T. et al. (2012)
    Effector CD4
    +
    CD45RA
    CD25
    bright
    Foxp3
    bright
    regulatory T cell (eTreg) distribution is significantly impaired in chronic myelomonocytic leukemia (CMML) and correlates with TET 2 mutational status.
    Blood 120: 2808-2808
  2. Baba, N. et al. (2010)
    Interplay between CD45RA
    +
    regulatory T cells and TNF-α in the regulation of human Tʜ17 differentiation.
    Int. Immunol. 22: 237-244
  3. Cantisan, S. et al. (2010)
    CD45RA expression on HCMV-specific effector memory CD8
    +
    T cells is associated with the duration and intensity of HCMV replication after transplantation.
    Clin. Immunol. 137(1): 81-88
  4. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  5. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  6. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  7. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  8. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  9. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22